Management of glaucoma in patients with nanophthalmos.

AIMS: In this retrospective study, we aimed to evaluate the results of glaucoma surgery in patients with nanophthalmos.

METHODS: Twenty-eight bilateral nanophthalmic patients, of whom 20 patients underwent trabeculectomy+Mitomycin-C (MMC)+inferior sclerotomy between 1996 and 2004, were included in this study. Records of patients with nanophthalmos were reviewed. Intraocular pressure (IOP), glaucoma medications, surgical success, visual acuity and complications were analyzed.

RESULTS: The mean IOP was 34.6+/-5.3 mm Hg preoperatively. At the final follow-up visit, the mean IOP dropped to 21.41+/-7.34 mm Hg (P<0.05). The cumulative probability of success was 85% at 1 year, 78.5% at 2 years, 76.9% at 3 years, 70.6% at 4 years and 47% at 5 years after surgery. Visual acuity decreased in 13 (65%) patients but no eye lost vision. Sequels of choroidal detachment (five patients 25%) and retinal folds (four patients 20%) were the most frequent reason for visual decrease. Uveal effusion (10 patients 50%) and cataract formation (seven patients 35%) were major late postoperative complications.

CONCLUSIONS: Results indicate that trabeculectomy+MMC+inferior sclerotomy procedure was effective and safe for glaucoma control in patients with nanophthalmos, but uveal effusion is a major problem and cataract surgery is expected in the long run.